#bharat biotech limited

[pharmawalksjobs]

Bharat Biotech - Walk-in for Production/ Engineering departments on 25th Jan 2025

Greetings from Bharat Biotech International Limited! We are conducting various roles in Production & Engineering departments on 25th January 2025 @ Hyderabad. Walk-in interview details Date of interview: 25th January 2025 Time: 10.00 AM – 2.00 PM Venue: Bharat Biotech International Limited, Genome Valley, Turkapally, Shamirpet, Hyderabad – 500078. Contact – HR Team (9014552718). We are hiring for…

[businessitblog]

product based companies in Hyderabad

Hyderabad, often referred to as the "City of Pearls," has swiftly emerged as a prominent center for information technology, pharmaceuticals, and manufacturing industries. With its dynamic business environment and strategic location, the city has become a preferred destination for product-based companies, fostering innovation, creating jobs, and significantly boosting the local and national economy.

This comprehensive exploration delves into the significance, challenges, and future potential of product-based companies in Hyderabad.

What Are Product-Based Firms in Hyderabad?

Product-based companies focus on creating, manufacturing, and selling tangible goods, ranging from software solutions and industrial machinery to everyday consumer products. Unlike service-based firms that deliver intangible services like consulting or customer support, these companies offer products that users can physically interact with.

Examples Include:

Consumer electronics

Pharmaceutical drugs

Automobile components

In Hyderabad, product-based companies span diverse sectors, each playing a crucial role in the city's industrial landscape and growth.

Why Hyderabad is Ideal for Product-Based Companies

1. Thriving Tech and Industrial EcosystemThe city hosts numerous industrial parks and Special Economic Zones (SEZs) that foster business growth. Multinational corporations like Microsoft, Amazon, and Google have established a strong presence, driving innovation and market expansion.

2. Skilled Workforce AvailabilityHyderabad boasts prestigious educational institutions such as the Indian School of Business (ISB) and the International Institute of Information Technology (IIIT), ensuring access to a pool of highly talented professionals.

3. Supportive Government PoliciesThe Telangana government promotes business growth through initiatives like TS-iPASS, simplifying industrial clearances and encouraging the establishment of product-based companies.

4. Strong Connectivity and InfrastructureWith the Rajiv Gandhi International Airport, comprehensive road networks, and rail links, Hyderabad ensures seamless logistics operations for product-focused enterprises.

Prominent Product-Based Companies in Hyderabad

Tech and IT Products:

Microsoft India Development Center: A key player in software innovation

Amazon Web Services (AWS): Leading provider of cloud-based solutions

Pharmaceutical and Biotech Products

Dr. Reddy's Laboratories: A global leader in pharmaceutical manufacturing.

Aurobindo Pharma: Renowned for its extensive range of generic drugs.

Automobile Components

Bharat Forge: Specializes in automotive parts forging.

ZF Group: A leader in driveline and chassis technology.

Consumer Goods

Procter & Gamble (P&G): Manufactures household goods.

ITC Limited: Offers packaged foods, personal care products, and more.

Key Benefits of Hyderabad's Product-Based Companies

Access to Talent and Innovation Hubs

Strong industry-academia collaborations fuel innovation.

A rich pool of engineers, researchers, and product designers.

Collaborative Environment

Numerous innovation hubs and R&D centres foster product development.

Export Market Expansion

Strategic location and superior connectivity facilitate access to both domestic and international markets.

Challenges Facing Product-Based Companies in Hyderabad

High Competition

The growing number of companies across various sectors intensifies market competition.

Logistics and Supply Chain Issues

Despite robust infrastructure, occasional delays in material sourcing and customs clearance can occur.

Talent Retention

The competitive job market makes retaining top talent a persistent challenge.

Emerging Sectors and Future Trends

IoT and Smart Devices

The demand for IoT products continues to rise, positioning Hyderabad as a key player.

Renewable Energy Products

Companies involved in manufacturing solar panels, wind energy components, and energy-efficient appliances are expanding rapidly.

Biotech and Healthcare Innovations

The sector is experiencing significant growth due to advancements in healthcare technology.

Steps to Start a Product-Based Company in Hyderabad

Market Research and Planning

Analyze market demand and assess the competitive landscape.

Develop a comprehensive business plan.

Legal Considerations

Register the company and obtain the necessary licenses.

Ensure compliance with safety and quality regulations.

Location Selection

Choose strategic locations near suppliers, customers, and logistics hubs.

Financing and Infrastructure

Explore funding options such as venture capital, government grants, or business loans.

Marketing and Distribution

Develop a robust marketing strategy.

Establish an efficient distribution network.

Conclusion

With its robust infrastructure, skilled workforce, and favorable business environment, Hyderabad presents a fertile ground for product-based companies. From technology and pharmaceuticals to consumer goods and automotive components, the city offers vast opportunities for entrepreneurs and established enterprises alike.

FAQs

What are the key sectors for product-based companies in Hyderabad? Key sectors include technology, pharmaceuticals, automobile components, and consumer goods.

How can I start a product-based company in Hyderabad? Begin with thorough market research, business registration, securing funds, and establishing a distribution network.

What challenges do product-based companies face in Hyderabad? Intense competition, logistics issues, and talent retention are common challenges.

Explore for more: MarketingHack4U - Marketing and Tech Blog

Best news portal development company in India

Best news portal development company in India

[biotichealthcare]

The report published by Kearney in collaboration with the Confederation of Indian Industry titled “Taking India’s life sciences industry to the global stage”, reported that “India’s vaccines industry can grow from $2 billion to $4 billion or even $5 billion”. This has been made possible by a number of factors prominent being the inclusion of vaccines in the product portfolios of several domestic and global pharmaceutical companies. With the pandemic kicking in 2019 end, the entire world came together to build an effective vaccine to fight against the deadly coronavirus.

This report speaks a lot about the Indian biosimilars and vaccines industries and how it is competing globally and scopes for India in the global biosimilars and vaccines industry. It lays down the challenges faced by the Indian pharmaceutical industry and how we can overcome these. It lays down abundant solutions to the challenges faced and how India can ace the Global Pharma sector and command its worthy position both in terms of volume and value.

Indian Vaccine Industry 

The global Pharmaceutical industry has made vaccines their priority. India commands a massive 40% share of the global vaccine industry by volume. India has been playing a pivotal role in combating deadly diseases for years and now the coronavirus pandemic. India is all set to grow to hold a more significant place in the global pharma industry in the coming years. With the introduction of newer and better technologies such as gene therapies, Ai-based informatics, etc has opened boundless opportunities to conduct research and experimentation and develop innovative and effective medications.

India already possesses a strong local pharma industry, fundamentally strong technical capabilities, and rich scientific acumen, that has helped us emerge as an innovational hub of the world. India is the global supplier of drugs and medicines and everybody prefers India for its low-cost manufacturing processes and affordable drugs.

However, Indian Pharmaceutical Industry still lags behind in terms of the value of our market share through being the third-largest volume producer. India faces several challenges that need to be overcome. COVID pandemic offers a great opportunity for India to take a step ahead to bag the top position both in terms of volume and value.

Massive Scope for Global Vaccine supply

There is abundant scope for the export of COVID-19 vaccines globally to countries unable to manufacture vaccines on their own. Moreover, there are several diseases globally that need vaccination, and these infectious diseases amount to more than 70% of the world population. Many countries rely on India for the supply of vaccine doses to combat various infectious diseases. Our own nation has a huge demand for vaccines owing to the huge population count and prevalence of abundant diseases such as diphtheria, tetanus, hepatitis B, measles, mumps, rubella, etc.

India has long been involved in supplying the highly required vaccines to several developing nations at the most affordable prices. So now also the world relied on India for COVID vaccine and India proved to be the biggest exporter of Covid vaccines globally. India itself faced a shortage of vaccines initially due to the heavy burden on the limited resources besides having huge commitments globally. Only two vaccine manufacturers i.e. Serum Institute of India (SII) and Bharat Biotech were operational in the beginning. With limited manufacturing resources, it became difficult to meet both domestic and global vaccine requirements.

This shows the scope for vaccine manufacturing in India provided we develop the required infrastructure and support our pharma medicine developers with the latest and advanced technologies to conduct their research. India requires a favorable statutory and political environment to lead the world with its pharmaceutical products. To be the global leader in terms of value, India needs to be more research-oriented to develop unique formulations to treat health conditions and obtaining Intellectual Property Rights. This is how India can occupy a major pharma share both in terms of volume as well as value.

[ranakaushal]

10th Annual Biotech Industry Conclave on Biotechnology for Humanity: Innovations Shaping a Better World

KIIT School of Biotechnology organized the 10th Biotech Industrial Conclave on “Biotechnology for Humanity: Innovations Shaping a Better World” during 23rd–24thAugust 2024. The conclave, spanning over two days, had enlightening talks, discussion and spirited interactions between experts from the biotech industry, academia, and students to foster collaboration and innovation in the field. During the inaugural session, Dr. Achyuta Samanta, Founder, KIIT & KISS, welcomed all the dignitaries and stressed upon development of strong collaboration between KIIT and biotechnology industry.

Padmashri Dr. Krishna Ella, Founder & Executive Chairman, Bharat Biotech International Limited echoed the need for close interaction between premier educational institutes and the biotech industry for inclusive growth. Dr. Ella, in his keynote address, shared his personal journey in entrepreneurship and innovation, highlighting the challenges and rewards of building a successful biotech company. He emphasized the importance of practical learning experiences for PhD students and the role of the Ella Foundation in supporting their entrepreneurial endeavors. He also stressed upon the need for vaccine development for neglected diseases.

Dr. Shilpa Gadgil, Vice President, Enzene Biosciences Ltd.; Dr. Priyabrata Pattnaik, Dy. Managing Director, Indian Immunologicals Ltd.; Raghavendra P. Rao, Principal Scientist, The Himalaya Drug Company; Dr. Ranendra N. Saha, Chief Scientific Advisor, Biophore; Dr. Sreedharala Venkata Nookaraju, Executive Vice President, Aizant Drug Research Soln. Lt;. and Dr. Prabuddha Kundu, Co-Founder & MD, Premas Biotech discussed about emerging trends in complex therapeutic biomolecules like monoclonal antibodies, novel vaccines, complex protein production processes. Mr. Dushyant Deshmukh, GM-HR, Glenmark Pharmaceuticals; Mr. Hemant Nikam, Sr Director and Head HR, Eisai Pharmaceuticals India; and Mr. Pritesh Bhatia, Associate Director HR, Jubilant Biosys Ltd. discussed about the emerging trends in human resource requirements and how students should prepare themselves to become successful biotechnology professionals.

Mr. Lalit Sisaudia, Vice President of Nutaste Group and Ms. Rosina Panda, Business Manager, Intertek spoke about food safety and the need for precision to address global food security challenges.

Dr. Emili Banerjee, Senior Genetic Counselor, Neuberg Diagnostics, Dr. Raghavendra Goud, Executive Director at PharmNXT Biotech and Mr. Ashish Dubey, Co-Founder and COO, Redcliffe Labs discussed the opportunities in molecular diagnostics in healthcare and how AI driven processes can accelerate disease detection and make healthcare accessible in the remote regions of the country. In the last session, five alumni turned entrepreneurs Mr. Pritam Dhalla, Founder, Larkai Healthcare; Mr. Akashdeep Dan, Co-Founder of Bogmalo Foods and Hospitality; Mr. Prateek Mahapatra, Director of Grow Green Consortium Pvt. Ltd.; Ms. Varsha Biswal, CEO, Trupti Dairy; and Dr. Shailesh Samal, CEO, Inflanova AB shared the memories in KSBT and how it helped them to excel in their areas of passion.

Dr. Mrutyunjay Suar, DG-Research & Innovation, and CEO, KIIT-TBI discussed about start-up innovation system in KIIT and role of Bhubaneswar City Knowledge Cluster in developing fruitful collaboration in the biotechnology sector. Dr. Jnyana Ranjan Mohanty, Registrar and Dr. Srinivas Patnaik, Dean KSBT described the academic initiatives taken for skill development of the students. Dr. Rahul Modak, Convener of the conclave thanked all the dignitaries and participants for their active participation and contribution in the conclave.

[rohanisblog]

India Specialty Drug Distribution Market generated a revenue of US$ 2,045.35 million in 2022 and is estimated to reach a valuation of US$ 5,997.7 million by 2031 at a CAGR of 12.93% during the forecast period 2023–2031.

Key Players in the Market Report 

Aark Pharmaceuticals

Astellas Pharma India Pvt. Ltd.

Aurobindo Pharmaceuticals

Arlak Biotech

Bharat Serums and Vaccines Limited

Biotic Healthcare

Cipla

D.Vijay Pharma

Dr. Reddy’s Laboratories Ltd

Divis Laboratories

Feron Healthcare

Gaia Pharmaceutical Trade

Glenmark Pharmaceuticals

GNova Biotech

Ikris Pharma

IMS Medi

Jay-Pharma

Lupin

Meher Distributors Pvt. Ltd.

Merck & Co., Inc.

Novartis AG

Novacare

Pax Healthcare

Prime Health

Sanify Healthcare

Serum Institute of India Pvt. Ltd.

Sun Pharmaceutical Industries Ltd.

Servocare Lifesciences

Shubham Pharmaceutical

Swisschem Healthcare

Torrent Pharmaceuticals

Vardhman Health Specialities Pvt. Ltd.

Zydus Lifesciences Limited

Intas Pharmaceuticals Ltd.

3S Corporation

Other Prominent Players

[digimarketresearch]

Chikungunya Treatment Market Size, Share, Trends, Growth and Competitive Outlook

"Global Chikungunya treatment Market study by Data Bridge Market Research provides details about the market dynamics affecting the Chikungunya treatment market, Market scope, Market segmentation and overlays shadow upon the leading market players highlighting the favourable competitive landscape and trends prevailing over the years.

An all-inclusive Chikungunya treatment market report enables clients to boost revenues from new and existing customer base as well as identify key trends and hidden opportunities, latest developments, market shares, and strategies that are employed by the major market players. Client or business can get aware of the impact of opportunities that are offered by the market and hence design sustainable and competitive strategies in times of rapid development. A range of definitions and classification of the Chikungunya treatment industry, applications of the Chikungunya treatment industry and chain structure are given in the credible Chikungunya treatment report.

Chikungunya treatment business document is also helpful to understand the regional analysis of the market and paradigm shift in consumer preferences. This report makes it easy to analyze various market perspectives with the help of Porter’s five forces analysis. The company profiles of all the top market players and brands with moves like product launches, joint ventures, mergers and acquisitions which in turn is affecting the sales, import, export, revenue and CAGR values are revealed in this market report. Key market dynamics of the Chikungunya treatment industry is the best part about Chikungunya treatment market research report.

Access Full 350 Pages PDF Report @

Data Bridge Market Research analyses that the chikungunya treatment will exhibit a CAGR of around 7.40% for the forecast period of 2021-2028. Rising prevalence of dengue in tropical and sub-tropical regions, increased government initiatives and funding to fight against dengue, surge in the research and development activities for the development of novel drugs and therapies and increased expenditure for the development of healthcare infrastructure are the major factors attributable to the growth of chikungunya treatment market.

Highlights of TOC:

Chapter 1: Market overview

Chapter 2: Global Chikungunya treatment Market

Chapter 3: Regional analysis of the Global Chikungunya treatment Market industry

Chapter 4: Chikungunya treatment Market segmentation based on types and applications

Chapter 5: Revenue analysis based on types and applications

Chapter 6: Market share

Chapter 7: Competitive Landscape

Chapter 8: Drivers, Restraints, Challenges, and Opportunities

Chapter 9: Gross Margin and Price Analysis

Countries Studied:

North America (Argentina, Brazil, Canada, Chile, Colombia, Mexico, Peru, United States, Rest of Americas)

Europe (Austria, Belgium, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Poland, Russia, Spain, Sweden, Switzerland, United Kingdom, Rest of Europe)

Middle-East and Africa (Egypt, Israel, Qatar, Saudi Arabia, South Africa, United Arab Emirates, Rest of MEA)

Asia-Pacific (Australia, Bangladesh, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Sri Lanka, Thailand, Taiwan, Rest of Asia-Pacific)

The major players covered in the chikungunya treatment market report are Merck KGaA, QIAGEN, Bio-Rad Laboratories, Danaher., Hologic, Inc., BD, Abbott, Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche Ltd, Siemens Healthcare GmbH, bioMérieux SA, Zydus Cadila, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited., Themis Bioscience GmbH, Bharat Biotech., Paradigm Biopharmaceuticals Ltd, Nano Therapeutics Pvt Ltd, Hawaii Biotech Inc. and Integral Molecular among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Browse Trending Reports:

Alzheimers Disease Diagnostic Market

Europe Hearing Aids Market

Smart Health Watches Market

Europe Hospital Furniture Market

Middle East And Africa Foot And Ankle Devices Market

About Data Bridge Market Research:

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact Us:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email: corporatesales@databridgemarketresearch.com"

[ramtracking]

Clinical trials of first adult TB vaccine derived from human source begins [ BCG vaccine ]

Clinical trials of first adult TB vaccine derived from human source begins [News Summary] Bharat Biotech International Limited, in collaboration with Biofabri, has started a series of clinical trials in adults in the country to… India News: HYDERABAD: Bharat Biotech, based in Hyderabad, has started clinical trials of MTBVAC, the world’s first Mycobacterium… World Tuberculosis (TB) Day is marked…

[aimarketresearch]

Chikungunya Treatment Market Size, Share, Trends, Demand, Growth and Competitive Outlook

Global Chikungunya treatment Market study by Data Bridge Market Research provides details about the market dynamics affecting the Chikungunya treatment market, Market scope, Market segmentation and overlays shadow upon the leading market players highlighting the favourable competitive landscape and trends prevailing over the years.

An all-inclusive Chikungunya treatment market report enables clients to boost revenues from new and existing customer base as well as identify key trends and hidden opportunities, latest developments, market shares, and strategies that are employed by the major market players. Client or business can get aware of the impact of opportunities that are offered by the market and hence design sustainable and competitive strategies in times of rapid development. A range of definitions and classification of the Chikungunya treatment industry, applications of the Chikungunya treatment industry and chain structure are given in the credible Chikungunya treatment report.

Chikungunya treatment business document is also helpful to understand the regional analysis of the market and paradigm shift in consumer preferences. This report makes it easy to analyze various market perspectives with the help of Porter’s five forces analysis. The company profiles of all the top market players and brands with moves like product launches, joint ventures, mergers and acquisitions which in turn is affecting the sales, import, export, revenue and CAGR values are revealed in this market report. Key market dynamics of the Chikungunya treatment industry is the best part about Chikungunya treatment market research report.

Data Bridge Market Research analyses that the chikungunya treatment will exhibit a CAGR of around 7.40% for the forecast period of 2021-2028. Rising prevalence of dengue in tropical and sub-tropical regions, increased government initiatives and funding to fight against dengue, surge in the research and development activities for the development of novel drugs and therapies and increased expenditure for the development of healthcare infrastructure are the major factors attributable to the growth of chikungunya treatment market.

Access Full 350 Pages PDF Report @

Highlights of TOC:

Chapter 1: Market overview

Chapter 2: Global Chikungunya treatment Market

Chapter 3: Regional analysis of the Global Chikungunya treatment Market industry

Chapter 4: Chikungunya treatment Market segmentation based on types and applications

Chapter 5: Revenue analysis based on types and applications

Chapter 6: Market share

Chapter 7: Competitive Landscape

Chapter 8: Drivers, Restraints, Challenges, and Opportunities

Chapter 9: Gross Margin and Price Analysis

Countries Studied:

North America (Argentina, Brazil, Canada, Chile, Colombia, Mexico, Peru, United States, Rest of Americas)

Europe (Austria, Belgium, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Poland, Russia, Spain, Sweden, Switzerland, United Kingdom, Rest of Europe)

Middle-East and Africa (Egypt, Israel, Qatar, Saudi Arabia, South Africa, United Arab Emirates, Rest of MEA)

Asia-Pacific (Australia, Bangladesh, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Sri Lanka, Thailand, Taiwan, Rest of Asia-Pacific)

The major players covered in the chikungunya treatment market report are Merck KGaA, QIAGEN, Bio-Rad Laboratories, Danaher., Hologic, Inc., BD, Abbott, Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche Ltd, Siemens Healthcare GmbH, bioMérieux SA, Zydus Cadila, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited., Themis Bioscience GmbH, Bharat Biotech., Paradigm Biopharmaceuticals Ltd, Nano Therapeutics Pvt Ltd, Hawaii Biotech Inc. and Integral Molecular among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Browse Trending Reports:

Respiratory Polygraphs Market

Biomedical Refrigerators And Freezers Market

Digital Mobile X Ray Devices Market

Point Of Care Poc Urinalysis Market

Viral Clearance Services Market

About Data Bridge Market Research:

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact Us:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email: corporatesales@databridgemarketresearch.com

[pharmawalksjobs]

Job opportunity for Production department at Bharat biotech

Bharat Biotech International Limited is a versatile biotechnology firm that focuses on research, development, and production of vaccines and biotherapeutics. The company is dedicated to creating advanced vaccines and bio-therapeutics through groundbreaking and cooperative research efforts. BBIL’s cutting-edge manufacturing facility stands as the largest in the Asia-Pacific region. Join Bharat…

[themarketinsights]

Vaccine Conjugate Market is set for a Potential Growth Worldwide: Excellent Technology Trends with Business Analysis

Latest released the research study on Global Vaccine Conjugate Market, offers a detailed overview of the factors influencing the global business scope. Vaccine Conjugate Market research report shows the latest market insights, current situation analysis with upcoming trends and breakdown of the products and services. The report provides key statistics on the market status, size, share, growth factors of the Vaccine Conjugate The study covers emerging player’s data, including: competitive landscape, sales, revenue and global market share of top manufacturers are Bharat Biotech (India), Biological E (India), CSL Limited (Australia), GlaxoSmithKline, plc. (U.K.), Merck and Company (U.S.), Neuron Biotech (U.S.), Novartis AG (Switzerland), Pfizer, Inc. (U.S.), Sanofi Pasteur (France), Serum Institute of India (India)

Free Sample Report + All Related Graphs & Charts @: https://www.advancemarketanalytics.com/sample-report/3382-global-vaccine-conjugate-market-1?utm_source=Organic&utm_medium=Vinay

Conjugate vaccines refer to those vaccines that contain bacterial capsule polysaccharide or conjugated to a protein or the antigen attached. This protein plays a vital role in enhancing the immunogenic property of the polysaccharide which helps to protect the body from microorganisms.

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Southeast Asia.

[sudheervanguri]

Bharat Biotech Fresher Jobs for Lifesciences Candidates: Ignite Your Career in Bioprocessing and Formulation Introduction Embark on an exciting journey with Bharat Biotech International Limited, a pioneer in the field of biopharmaceuticals. This blog post unveils exclusive opportunities for freshers in the Production Department, focusing on Bio Process and Formulation & Filling. Dive into the details about the company, available job positions, and how to apply for these promising roles. About the Company Bharat Biotech International Limited Bharat Biotech International Limited stands at the forefront of the biopharmaceutical industry, contributing to global healthcare through innovative vaccines and biotherapeutics. Committed to research, development, and manufacturing, Bharat Biotech has earned a stellar reputation for its contributions to public health. Company Vacancies List Position Title: Production Trainee Company Name: Bharat Biotech International Limited Salary: As Per Company Norms Company Address: Hyderabad, India Role: Production Trainee Industry Type: Biopharmaceuticals Department: Production (Bio Process / Formulation & Filling) Employment Type: Full-time Role Category: Production Education UG: B.Sc (Chemistry/Biotechnology) / B.Pharmacy / B.Tech Biotech / Diploma/ITI PG: M.Sc (Chemistry/Biochemistry/Biotechnology) [caption id="attachment_57664" align="aligncenter" width="930"] Bharat Biotech Hiring Production Executives in Hyderabad - Apply Now[/caption] Key Skills Bioprocessing, Formulation & Filling, Production, Biochemistry, Biotechnology How to Apply Interested candidates are invited to share their updated CVs with "careers@bharatbiotech.com". Please mention "Production Trainee" in the subject line.

[thenewsfactsnow]

Bharat Biotech and University of Sydney Sign MoU to Advance Academic and Vaccine Research Collaboration

Hyderabad, India, and Sydney, Australia – 28th November 2023 – Bharat Biotech International Limited, a world leading vaccines & bio-therapeutics manufacturer and the University of Sydney Infectious Diseases Institute (Sydney ID) today announced a Memorandum of Understanding (MoU) to advance vaccine research initiatives, strengthen academic-industry partnerships and augment global efforts to…

[digitalmarketing923]

Clinical Trials Being Taken Up In India For Cholera Vaccines

Cholera is a bacterial infection that causes diarrhea, which kills the patients within hours, if left untreated. If patients are diagnosed in time, and treated with antibiotics and other measures at an early stage, they can recover and get back to their normal lives, but if not, they may have to lose their life! Cholera infects approximately 2.8 million people, causing 95,000 deaths every year! In 2018, there was a global demand for around 100 million doses of cholera vaccine, but the supply was only somewhere around 20 million; so you can imagine the sad face of the outbreak!

Today, the world relies only on two suppliers for cholera vaccines – one from South Korea, and the other from India; but, the global demand for cholera vaccines is higher than the supply. This is why large-scale clinical trials are being planned to be conducted, and a Swedish-designed cholera vaccine is to be commercialized to help fight persistent outbreaks of cholera in India and abroad.

The Hilleman-Bharat pact

It is the Hyderabad-based Bharat Biotech that signed a pact with the New Delhi-based Hilleman Laboratories to speed up the development and clinical trials. Also, the manufacture of the new oral cholera vaccine needs to be accelerated for the drug to be supplied to low and middle income countries. This collaboration of Bharat Biotech and Hilleman Laboratories has been mainly done to address the global shortage of cholera vaccines, in the midst of the persistence of outbreaks in several states across India and Africa.

What is the pact about?

Under the pact, Hilleman laboratories have licensed to Bharat Biotech the vaccine designed by scientists at the University of Gothenburg, Sweden. The vaccine’s safety and capacity to produce an immune response to cholera has already been established by Hilleman laboratories through limited Phase-1 and Phase-2 clinical trials in Bangladesh. Bharat Biotech, thus, has to conduct larger Phase-3 trials and scale up the vaccine production process for commercialization, while also seeking a pre-qualification certification from the World Health Organization, to enable it to supply the vaccine through global funding agencies. The entire process may take somewhere around three years, but the capacity to deliver 50 million doses every year will resolve the uncertainty over supply.

Cholera widespread in India

In India, the highest risk of cholera is in Bengal. In fact, Ancient Asiatic cholera strains have also thrived in the Ganges delta, making Bengal very unsurprisingly the most highly affected state. In fact, almost 50% of cholera cases seen in India every year have been in Bengal. Next in line come Karnataka, Gujarat, Maharashtra, Punjab, Odissa, and Assam. With a goal to produce an affordable vaccine that improves access to millions of cholera patients not only in India, but worldwide too, the vaccine that is being tested could be a key tool in the Narendra Modi government’s Swachh Bharat Abhiyaan campaign, which seeks to improve the levels of sanitation, and the access to clean drinking water.

Get yourself the best quality online clinical research training from Avigna Clinical Research Institute to establish a career in the clinical research industry, so that even you can put in your efforts and inputs to help your country, and the entire world, fight many such conditions like the life-threatening cholera! And, if you are worried about the associated expenses, worry not, the Indian Government has launched a scheme called SPARC, wherein the government will fund interested clinical research students and give them a chance to work in at least 28 global universities!

[riyaseo6]

N Chandrababu Naidu's Vision of Transforming Hyderabad Into Genome Valley

In the late 20th century, the global landscape witnessed a rapid convergence of technology and life sciences. Recognizing the potential of this intersection, Nara Chandrababu Naidu, the visionary leader of the Telugu Desam Party (TDP), embarked on a mission to transform Hyderabad into a hub of innovation and progress. This TDP agenda marked the birth of Genome Valley, a groundbreaking biotechnology park that would catalyze economic growth and establish India's prominence in the biopharmaceutical sector. In 1999, N. Chandrababu Naidu introduced the Pharma City project, a state-of-the-art biotechnology park situated to the north of Hyderabad. His forward-thinking approach aimed to attract leading multinational pharmaceutical companies and biotech giants to invest in the region. Leveraging the city's strategic location, skilled workforce, and proactive Political schemes, Chandrababu Naidu envisioned Genome Valley as a haven for scientific research, technological advancement, and economic development.

The TDP policies played a pivotal role in realizing Nara Chandrababu Naidu's ambitious plans. Recognizing the significance of a conducive business environment, the TDP party implemented investor-friendly policies that facilitated the establishment and growth of businesses in the region. Tax incentives, streamlined regulatory procedures, and infrastructure development were among the measures undertaken to lure companies to Hyderabad. This holistic approach helped overcome barriers that often deter international corporations from investing in emerging markets. N Chandrababu Naidu's persuasive prowess came to the forefront as he reached out to prominent multinational pharmaceutical and biotech companies, including Novartis Pharma India, Shantha Biotechnics, Bharat Biotech, Biocon, Biological E. Limited, and Jupiter Biosciences. He personally engaged with global CEOs, making compelling presentations that showcased Hyderabad's potential as a fertile ground for innovation and growth. His relentless efforts and the TDP leaders’ commitment to creating a world-class biotechnology ecosystem played a pivotal role in attracting these companies to Genome Valley.

The synergy between N Chandrababu Naidu's vision and the TDP schemes resulted in a remarkable transformation. Genome Valley rapidly became a bustling hub of scientific research, biopharmaceutical manufacturing, and technological innovation. Novartis, Shantha Biotechnics, Bharat Biotech, Biocon, and other multinational corporations set up their operations in Hyderabad, capitalizing on the ecosystem that had been meticulously cultivated. However, Nara Chandrababu Naidu's ambitions extended beyond biotechnology. Recognizing the integral role of information technology (IT) in the global economy, he also targeted global IT giants like IBM, Dell, HSBC, and Oracle Corporation. Chandrababu Naidu's persuasive skills and the attractive business climate in Hyderabad convinced these tech behemoths to establish their offices in the city. This TDP contribution not only helped Hyderabad's economic growth but also solidified its status as a hub for both life sciences and technology.

The success of Genome Valley and Hyderabad's transformation into a thriving economic centre can be attributed to Nara Chandrababu Naidu's vision, leadership, and the TDP's innovative policies. The holistic approach encompassing infrastructure development, investor-friendly measures and policy, and strategic partnerships propelled the region into the global spotlight. Through the TDP party news and Live updates from the official website, know about N Chandrababu Naidu's efforts and the TDP developments in exemplifying proactive governance, engaging with international leaders, and personally advocating for Hyderabad's potential. In conclusion, N. Chandrababu Naidu's establishment of Genome Valley and his pursuit of a diverse economic landscape through the implementation of TDP policies was a watershed moment in Hyderabad's history. His legacy continues to shape the region's identity as a beacon of innovation, research, and economic progress. This TDP achievement of Genome Valley stands as a testament to the power of visionary leadership, strategic policies, and unwavering determination to drive growth and transformation.

[delicatemagazinedreamer]

Global Bacterial Vaccines Market Is Estimated To Witness High Growth Owing To Increasing Focus on Preventive Healthcare

The global Bacterial Vaccines Market is estimated to be valued at US$ 23.77 billion in 2023 and is expected to exhibit a CAGR of 8% over the forecast period, as highlighted in a new report published by Coherent Market Insights. Bacterial vaccines are products designed to stimulate the body's immune response against bacterial infections. These vaccines are used to prevent or treat various bacterial diseases such as pneumonia, meningitis, and typhoid fever. Market Overview: Bacterial vaccines play a crucial role in preventive healthcare, as they help to reduce the burden of bacterial infections. The rising prevalence of infectious diseases worldwide has led to an increased demand for bacterial vaccines. Moreover, the growing awareness about the benefits of vaccination and the government initiatives promoting immunization programs have further boosted market growth. Bacterial vaccines offer several advantages, including long-term protection, reduced transmission of infectious diseases, and cost-effectiveness compared to other treatment options. Market Key Trends: One key trend in the bacterial vaccines market is the increasing focus on the development of novel vaccine formulations. Manufacturers are investing in research and development to develop innovative vaccine formulations that provide broader protection against multiple bacterial strains. For example, GlaxoSmithKline plc is developing a multivalent pneumococcal conjugate vaccine that provides protection against several strains of Streptococcus pneumoniae. PEST Analysis: Political: Governments across the globe are actively involved in promoting immunization programs to reduce the burden of infectious diseases. They are implementing policies and regulations to ensure the availability and accessibility of bacterial vaccines. Economic: The growing healthcare expenditure and increasing investments in research and development activities are driving market growth. The cost-effectiveness of bacterial vaccines compared to other treatment options also contributes to market expansion. Social: The awareness about the benefits of vaccination and the importance of preventive healthcare is increasing among the general population. The demand for bacterial vaccines is rising as individuals are becoming more conscious about protecting themselves and their families from infectious diseases. Technological: Advances in technology have led to the development of new vaccine formulations and improved manufacturing processes. Innovative technologies such as viral vector-based vaccines and adjuvants are being used to enhance the efficacy of bacterial vaccines. Key Takeaways: In terms of market size, the global Bacterial Vaccines Market Size is expected to witness high growth, exhibiting a CAGR of 8% over the forecast period, due to increasing focus on preventive healthcare. The rising prevalence of infectious diseases and the growing awareness about the benefits of vaccination are driving market growth. In terms of regional analysis, North America is expected to be the fastest-growing and dominating region in the bacterial vaccines market. The region has a well-established healthcare infrastructure and a high adoption rate of advanced medical technologies. Moreover, the presence of key market players such as Pfizer Inc., Merck & Co. Inc., and Johnson & Johnson further contributes to the growth of the market in this region. Key players operating in the global bacterial vaccines market include GlaxoSmithKline plc, Pfizer Inc., Merck & Co. Inc., Sanofi Pasteur SA, Johnson & Johnson, Serum Institute of India Pvt. Ltd., Bharat Biotech International Limited, Biological E. Limited, Astellas Pharma Inc., Seqirus (CSL Limited), Mitsubishi Tanabe Pharma Corporation, Novavax Inc., Bavarian Nordic, Emergent BioSolutions Inc., and Valneva SE. These players are focusing on strategic collaborations, acquisitions, and product launches to strengthen their market presence and expand their product portfolio.

[ramtracking]

Clinical trials of first adult TB vaccine derived from human source begins [ India ]

Clinical trials of first adult TB vaccine derived from human source begins [News Summary] Bharat Biotech International Limited, in collaboration with Biofabri, has started a series of clinical trials in adults in the country to… India News: HYDERABAD: Bharat Biotech, based in Hyderabad, has started clinical trials of MTBVAC, the world’s first Mycobacterium… World Tuberculosis (TB) Day is marked…